Mounjaro in Dubai
Tirzepatide pricing in AED, where to fill a prescription, insurance coverage gaps, and how Mounjaro compares to other GLP-1 options available in the UAE market as of 2026.
Mounjaro (tirzepatide) is available in Dubai through hospital pharmacies and specialist clinics, but not yet widely stocked in community pharmacies. Monthly cost ranges from AED 1,500 to AED 2,500 depending on dose, and most UAE insurance plans do not cover it for weight management. A valid prescription from a licensed healthcare provider is required. It produces more weight loss than Ozempic or Wegovy in clinical trials (22.4% vs 14.9%), but at a higher price point. For research purposes, the investigational triple agonist retatrutide (24.2% weight loss in Phase 2) is the only compound to exceed tirzepatide’s clinical efficacy and is available in prefilled pen format from research suppliers in Dubai.
Janoshik-verified, HPLC ≥99.2% purity. Retatrutide Pen 30 mg from AED 1,000/pen. Ships from Dubai.
| Dose | Phase | Est. Monthly Cost (AED) | Notes |
|---|---|---|---|
| 2.5 mg | Titration (weeks 1–4) | AED 1,500–1,700 | Starting dose, 4 weekly pens |
| 5 mg | Titration (weeks 5–8) | AED 1,600–1,800 | First maintenance-eligible dose |
| 7.5 mg | Escalation | AED 1,800–2,000 | Optional step |
| 10 mg | Escalation | AED 2,000–2,200 | Most common maintenance dose |
| 12.5 mg | Escalation | AED 2,100–2,300 | Optional step |
| 15 mg | Maximum | AED 2,300–2,500 | Maximum dose, highest efficacy |
Where to Get Mounjaro in Dubai
As of early 2026, Mounjaro (tirzepatide) distribution in the UAE remains concentrated in the hospital and specialist clinic channels. Community pharmacies do not routinely stock it. Patients seeking tirzepatide in Dubai will generally need to go through one of the following pathways:
Hospital Pharmacies
Hospital-based pharmacies attached to major healthcare groups are the most reliable source. These facilities maintain cold-chain storage for injectable biologics and can dispense Mounjaro with an in-house prescription. Availability has been reported at facilities across Dubai Healthcare City, DIFC-adjacent clinics, and major hospital campuses throughout the emirate.
Specialist Clinics
Endocrinology and obesity medicine clinics with on-site dispensing can prescribe and supply Mounjaro directly. These clinics typically handle the prescription, clinical monitoring, and dispensing as an integrated service. This is the most common pathway for patients using Mounjaro for weight management rather than diabetes.
Prescription Requirements
Mounjaro is a prescription-only medication in the UAE. It cannot be purchased over the counter. Prescriptions are issued after clinical evaluation by a licensed healthcare provider—typically an endocrinologist, obesity medicine specialist, or internal medicine physician. Patients will need baseline blood work (HbA1c, thyroid function, lipid panel) before starting treatment.
Insurance Coverage in the UAE
Most UAE health insurance plans do not cover Mounjaro when prescribed for weight loss. The coverage gap exists because the majority of policies classify GLP-1 receptor agonists as elective treatments when used for obesity management.
- Weight management: Generally not covered. Patients pay the full AED 1,500–2,500 monthly cost out of pocket
- Type 2 diabetes: Partial coverage may be available under some enhanced plans, but pre-authorisation is typically required and not all insurers have added tirzepatide to their formularies
- Employer plans: Some multinational employer-sponsored plans with global formularies may cover Mounjaro, but this is uncommon in standard UAE group policies
Patients should confirm coverage with their insurer and obtain pre-authorisation before filling a prescription to avoid unexpected out-of-pocket costs. For a broader analysis of GLP-1 pricing across the UAE, see our GLP-1 medications UAE guide.
| Drug | Active Ingredient | Receptors | Max Weight Loss | Dubai Cost/Month |
|---|---|---|---|---|
| Ozempic | Semaglutide 0.25–1 mg | GLP-1 (1) | ~15% (STEP 1*) | AED 744–1,200 |
| Wegovy | Semaglutide 2.4 mg | GLP-1 (1) | 14.9% (STEP 1) | AED 1,200–1,500 |
| Saxenda | Liraglutide 3.0 mg | GLP-1 (1) | 8.0% (SCALE) | AED 800–1,100 |
| Mounjaro | Tirzepatide 2.5–15 mg | GLP-1 + GIP (2) | 22.4% (SURMOUNT-1) | AED 1,500–2,500 |
| Retatrutide* | Retatrutide 12 mg | GLP-1 + GIP + GCGR (3) | 24.2% (Phase 2) | From AED 1,000/pen |
*Ozempic’s STEP 1 result uses the higher 2.4 mg Wegovy dose, not Ozempic’s standard 1 mg dose. Retatrutide is an investigational compound not yet approved by any regulatory authority—available for research purposes only. For a detailed head-to-head analysis, see our retatrutide vs tirzepatide vs CagriSema comparison.
Mounjaro vs Ozempic in Dubai
Both Mounjaro and Ozempic are available in Dubai, but they differ significantly in efficacy, mechanism, and cost. The choice between them involves balancing clinical outcomes against monthly expense and availability.
- Efficacy: Tirzepatide 15 mg achieves roughly 50% more weight loss than semaglutide 1 mg in head-to-head trials (SURPASS-2: 13.1% vs 6.7%)
- Mechanism: Mounjaro activates two receptors (GLP-1 + GIP) versus Ozempic’s single GLP-1 receptor. The added GIP agonism contributes to greater appetite suppression and metabolic improvement
- Cost: Mounjaro costs approximately AED 750–1,300 more per month than Ozempic in Dubai
- Availability: Ozempic is more widely available in UAE pharmacies. Mounjaro requires sourcing from hospital pharmacies or specialist clinics
- Side effects: Both produce similar GI side effects (nausea, diarrhea, vomiting). Rates are comparable at equivalent titration stages. For detailed safety data, see our side effect comparison. For retatrutide-specific adverse events including the dysesthesia signal, see our retatrutide side effects profile
For patients whose primary goal is maximum weight reduction and who can manage the higher cost, Mounjaro is the more effective option based on available trial data. For those prioritising affordability and ease of access, Ozempic remains a strong first-line choice. For a complete breakdown of all injectable options, see our weight loss injection comparison guide.
Beyond Mounjaro — Next-Generation Research
While Mounjaro represents the current clinical standard for dual-agonist therapy, the obesity pharmacology pipeline has moved beyond two-receptor compounds. The most notable advancement is the triple agonist class, which adds glucagon receptor (GCGR) activation to the GLP-1/GIP dual-agonist foundation.
Retatrutide, the leading triple agonist in clinical development, achieved 24.2% mean weight loss at the 12 mg dose in Phase 2 trials—exceeding tirzepatide’s 22.4% maximum. The added glucagon receptor component contributes to increased energy expenditure and enhanced hepatic lipid oxidation, mechanisms not present in Mounjaro’s dual-agonist profile. For a complete mechanism analysis, see our triple agonist pathway guide. For retatrutide titration protocols and dosing schedules, see the retatrutide dosage guide.
Retatrutide is not yet approved by any regulatory authority. Eli Lilly’s Phase 3 TRIUMPH programme is expected to report results in 2026, with potential approval in late 2026 or early 2027. In the interim, retatrutide is available in Dubai as a research compound in prefilled pen format. For details on research availability, see our retatrutide in Dubai guide.
Retatrutide Pen 30 mg
99.262% HPLC purity, Janoshik Analytical. 300 clicks per pen, ships from Dubai.
Order Retatrutide Pen →Our Research Standards
This article cites peer-reviewed studies, FDA filings, and ClinicalTrials.gov data. All claims are cross-referenced against primary sources. We update articles when new trial data or regulatory decisions are published. Read our editorial policy →
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216. (SURMOUNT-1)
- Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503-515. (SURPASS-2)
- Wadden TA, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity. Lancet. 2023;402:P1718-1730. (SURMOUNT-3)
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity. JAMA. 2024;331:38-48. (SURMOUNT-4)
- Jastreboff AM, et al. Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for people with obesity. N Engl J Med. 2023;389:514-526.
- UAE Ministry of Health and Prevention. MoHAP Circular 17/2022 — Regulation of Peptide Research Compounds.
Remy Peptides supplies HPLC-verified retatrutide pens for research in Dubai. Learn more →